Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Digestive system drugs >  Appetite suppressants and other diet pills >  Selegiline

Selegiline

Basic information Safety Supplier Related

Selegiline Basic information

Product Name:
Selegiline
Synonyms:
  • SELEGILINE BASE
  • dl-Depreny
  • phenylisopropyl-n-MethylpropinylaMine
  • BenzeneethanaMine, N,a-diMethyl-N-2-propyn-1-yl-, (aR)-
  • R(-)-Selegiline solution
  • SELEGELIN
  • SELEGILINE
  • R(-)-SELEGILINE
CAS:
14611-51-9
MF:
C13H17N
MW:
187.28
EINECS:
604-507-3
Mol File:
14611-51-9.mol
More
Less

Selegiline Chemical Properties

Melting point:
137.5-139 °C
alpha 
D20 -11.2°
Boiling point:
273℃
Density 
0.954
refractive index 
nD20 1.5180
Flash point:
108℃
storage temp. 
-20°C
pka
7.53±0.50(Predicted)
InChI
InChI=1/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/s3
InChIKey
MEZLKOACVSPNER-PLAQIDKDNA-N
SMILES
C1(C=CC=CC=1)C[C@@H](C)N(C)CC#C |&1:7,r|
CAS DataBase Reference
14611-51-9
More
Less

Safety Information

Hazard Codes 
F,T
Risk Statements 
11-23/24/25-39/23/24/25
Safety Statements 
7-16-36/37-45
RIDADR 
1851
WGK Germany 
1
HazardClass 
6.1(b)
PackingGroup 
III
More
Less

Selegiline Usage And Synthesis

Description

Selegiline, a monoamine oxidase (MAO) inhibitor, is FDA-approved as an adjunct treatment in the management of patients with Parkinson disease and as a treatment for a major depressive disorder (MDD) in adults. Selegiline is also used off-label for early Parkinson disease and the treatment of attention-deficit/hyperactivity disorder (ADHD). 

Uses

Antidyskinetic; antiparkinsonian (in combination with levodopa/carbidopa).

Uses

This drug is a selective inhibitor of monoaminooxidase B, which suppresses dopamineinactivation processes and facilitates an increase of its level in the brain. In treating Parkinsonism, selegiline is usually used in combination with levodopa.

Definition

ChEBI:(-)-selegiline is a selegiline and a terminal acetylenic compound. It has a role as a geroprotector. It is a conjugate base of a (-)-selegiline(1+).

brand name

Emsam (Somerset).

World Health Organization (WHO)

Selegiline was introduced in the early 1990s. It is a monoamine oxidase inhibitor and is used in the management of Parkinson's disease. A symptomatic effect of selegiline in Parkinson's disease has been shown, but longer follow-up failed to provide any definitive evidence of ability to retard the loss of dopaminergic neurons (Parkinson's Study Group, 1993).

Biological Functions

Another drug used in the treatment of Parkinson’s disease is selegiline (also known as deprenyl, or Eldepryl). It is an irreversible inhibitor of MAO-B, an important enzyme in the metabolism of dopamine (Fig. 33.2). Blockade of dopamine metabolism makes more dopamine available for stimulation of its receptors. Selegiline, as monotherapy, may be effective in the newly diagnosed patient with parkinsonism because its pharmacological effect enhances the actions of endogenous dopamine.
Selegiline is also used in conjunction with levodopa– carbidopa in later-stage parkinsonism to reduce levodopa dosage requirements and to minimize or delay the onset of dyskinesias and motor fluctuations that usually accompany long-term treatment with levodopa. It has also been proposed that selegiline may slow the progression of the disease by reducing the formation of toxic free radicals produced during the metabolism of dopamine. However, any neuroprotective effect of selegiline in parkinsonian patients remains to be established.
Most of the adverse reactions to selegiline are related to actions of increased levels of dopamine, as discussed earlier. At recommended doses, and unlike the nonselective MAO inhibitors used in the treatment of depression, selegiline has little effect on MAO-A and therefore generally does not cause the hypertension associated with the ingestion of tyramine-enriched foods. However, at doses higher than those usually recommended, MAO-A may be inhibited, which increases the risk of a tyramine reaction.
Selegiline should not be coadministered with tricyclic antidepressants or selective serotonin uptake inhibitors because of the possibility of a severe adverse drug reaction (e.g., hyperpyrexia, agitation, delirium, coma).

Synthesis

Selegiline, N-methyl-N-(2-propinyl)-2-methyl-1-phenylethylamine (10.1.14), is synthesized by the alkylation of (-)methyamphetamine (8.1.2.3) using propargylbromide [20¨C23].

SelegilineSupplier

LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com
Shenzhen Pharma Technology Co., Ltd.
Tel
0755-86648230
Email
pharma08@sina.com
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Email
waley188@sohu.com
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Email
sales@sunlidabio.com
DebyeTec.com Inc.
Tel
18086626237 18086626237
Email
sales@debyesci.com